Literature DB >> 22171646

A national study of pain in the bleeding disorders community: a description of haemophilia pain.

M Witkop1, A Lambing, G Divine, E Kachalsky, D Rushlow, J Dinnen.   

Abstract

UNLABELLED: The National Pain Study was a prospective, computer-based, descriptive survey of the pain experience of persons with a bleeding disorder conducted in the United States over a 28 month period from 2007 to 2009. The aim of this study was to (i) determine the language used by patients to describe and differentiate acute and persistent pain, (ii) describe pharmacological and non-pharmacological strategies utilized to control pain, (iii) assess the perceived effectiveness of current pain management on quality of life and, (iv) to determine who provides pain management to this population. One thousand, one hundred and four surveys were received. Only the responses of the 764 respondents who reported having hemophilia A or B were evaluated for this paper. Thirty nine percent of participants reported their pain was not well treated. The average acute pain score associated with a bleed reported was 5.97/10 while the average persistent pain score reported was 4.22/10. The most frequently reported word descriptors for acute pain were: throbbing, aching, sharp, tender and miserable. The most frequently reported word descriptors for persistent pain were aching, nagging, tiring, sharp, and tender. The most frequently reported pain strategies for acute and persistent pain included factor, rest, ice, elevation, and compression. Alcohol and illicit drugs were reportedly used to manage both acute pain as well as persistent pain. Primarily, short-acting opioids and acetaminophen were reported to treat both acute and persistent pain. Hematologists and primary care providers provide the majority of pain management for persons with hemophilia (PWH). Quality of life (QOL) scores were lowest in the domains of pain, energy/fatigue and physical problems indicating disruption of QOL. This substantiates under-recognition and under-treatment of pain in the hemophilia population when combined with the 39% of respondents who felt their pain was not well treated and literature in the general pain population of wide spread under-treatment of pain. RECOMMENDATIONS: The NPS is an initial step in recognizing the prevalence and description of pain in PWH. HTC providers should educate themselves in pain management techniques to better serve this population. Further research is necessary to develop specific pain management guidelines for the bleeding disorders population that include multimodal holistic treatment plans.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 22171646     DOI: 10.1111/j.1365-2516.2011.02709.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  17 in total

1.  Health care resource utilization and cost burden of hemophilia B in the United States.

Authors:  Tyler W Buckner; Iryna Bocharova; Kaitlin Hagan; Arielle G Bensimon; Hongbo Yang; Eric Q Wu; Eileen K Sawyer; Nanxin Li
Journal:  Blood Adv       Date:  2021-04-13

Review 2.  Recent advances in musculoskeletal physiotherapy for haemophilia.

Authors:  David Stephensen; Melanie Bladen; Paul McLaughlin
Journal:  Ther Adv Hematol       Date:  2018-07-02

Review 3.  [Pain therapy for children and adolescents with hemophilia : Recommendations by an expert panel].

Authors:  W Stromer; B Messerer; R Crevenna; S H Hemberger; B Jauk; R Schwarz; W Streif; K Thom; B Wagner; K Zwiauer; R Likar
Journal:  Schmerz       Date:  2018-12       Impact factor: 1.107

4.  Effects of a pain self-management intervention combining written and video elements on health-related quality of life among people with different levels of education.

Authors:  Carol Stalker; James Elander
Journal:  J Pain Res       Date:  2015-08-20       Impact factor: 3.133

5.  Racial Differences in Chronic Pain and Quality of Life among Adolescents and Young Adults with Moderate or Severe Hemophilia.

Authors:  John M McLaughlin; Angela Lambing; Michelle L Witkop; Terry L Anderson; James Munn; Bartholomew Tortella
Journal:  J Racial Ethn Health Disparities       Date:  2015-04-03

6.  Reliability of patient-reported outcome instruments in US adults with hemophilia: the Pain, Functional Impairment and Quality of life (P-FiQ) study.

Authors:  Christine L Kempton; Michael Wang; Michael Recht; Anne Neff; Amy D Shapiro; Amit Soni; Roshni Kulkarni; Tyler W Buckner; Katharine Batt; Neeraj N Iyer; David L Cooper
Journal:  Patient Prefer Adherence       Date:  2017-09-19       Impact factor: 2.711

7.  Effectiveness of two psychological interventions for pain management, emotional regulation and promotion of quality of life among adult Portuguese men with haemophilia (PSY-HaEMOPEQ): study protocol for a single-centre prospective randomised controlled trial.

Authors:  Patrícia Ribeiro Pinto; Ana Cristina Paredes; Patrício Costa; Manuela Carvalho; Manuela Lopes; Susana Fernandes; Susana Pedras; Armando Almeida
Journal:  BMJ Open       Date:  2017-09-03       Impact factor: 2.692

8.  Predictors of quality of life among adolescents and young adults with a bleeding disorder.

Authors:  John M McLaughlin; James E Munn; Terry L Anderson; Angela Lambing; Bartholomew Tortella; Michelle L Witkop
Journal:  Health Qual Life Outcomes       Date:  2017-04-07       Impact factor: 3.186

9.  Internal consistency and item-total correlation of patient-reported outcome instruments and hemophilia joint health score v2.1 in US adult people with hemophilia: results from the Pain, Functional Impairment, and Quality of life (P-FiQ) study.

Authors:  Michael Wang; Katharine Batt; Craig Kessler; Anne Neff; Neeraj N Iyer; David L Cooper; Christine L Kempton
Journal:  Patient Prefer Adherence       Date:  2017-10-25       Impact factor: 2.711

10.  Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with haemophilia B receiving on-demand therapy.

Authors:  F Shafer; L Smith; N Vendetti; P Rendo; M Carr
Journal:  Haemophilia       Date:  2013-11-29       Impact factor: 4.287

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.